Anavex Loses Its Chair And Two Other Directors In One Day Over Strategy Differences

Jiong Ma, Gautam Patel and Adrian Senderowicz each resigned October 28, and the board reshuffled its three committees November 1.

Share
Anavex Loses Its Chair And Two Other Directors In One Day Over Strategy Differences

Three directors of Anavex Life Sciences, a clinical-stage biotech, resigned together on Wednesday, October 28, including board Chair Jiong Ma, each saying their views on strategy no longer matched those of the board and management, an 8-K filed Monday shows.

Three exits, one stated reason

Dr. Ma also sat on the Audit Committee. Gautam Patel was an Audit Committee member, and Dr. Adrian Senderowicz held no committee seats. All three resignations took effect October 28.

In her resignation letter, Ma called the decision "a very difficult one" and wrote that her views on the company's strategic direction "are not fully aligned with those of the Board and management." She wished the company and its shareholders continued success.

Patel and Senderowicz each concluded that their personal views on the strategy to execute the business plan do not sufficiently align with the board and management, according to the filing.

A reshuffled committee roster

On November 1, the board approved a new lineup for its three standing committees:

  • Audit: Dr. Claus van der Velden (chair), Dr. Peter Donhauser and Dr. Axel Paeger.
  • Compensation: Donhauser (chair) and van der Velden.
  • Nominating & Corporate Governance: Paeger (chair) and Donhauser.

The company behind the board

Anavex develops treatments for central nervous system diseases, including Alzheimer's, Parkinson's, schizophrenia and rare conditions such as Rett syndrome. Its lead candidate, ANAVEX 2-73, also called blarcamesine, is in three clinical trial indications, and ANAVEX 3-71 is in one, according to its annual report for the fiscal year ended September 30, 2025.

The company describes itself as a developer of therapies, not a seller of approved products.

Anavex said it will file any letters from the three departing directors saying whether they agree with its disclosure as an exhibit to an amended 8-K within two business days of receiving them.

Sources

More on Anavex Life Sciences

All Anavex Life Sciences (AVXL) coverage →